AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05225701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic self-guided internet-delivered intervention
Description: Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
Study NCT06044168 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Leucine
Description: 150mg/kg body mass/day
Study NCT05467995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
Study NCT05467995 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
Study NCT06126341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychosocial Assessments of Candidates for Transplantation
Description: The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
Study NCT06277661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMI PODS
Description: MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
Study NCT06277661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
Study NCT05040568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT05040568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded CB-NK cells
Description: Given IV
Study NCT05040568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given IV
Study NCT05040568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05783414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: f2f CST
Description: An evidence-based group CST protocol adapted for Hong Kong Chinese culture. It consists of 14 sessions of group activities (group size: 6) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
Study NCT05783414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: f2f CST
Description: An evidence-based group CST protocol adapted for Hong Kong Chinese culture. It consists of 14 sessions of group activities (group size: 6) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
Study NCT05783414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: f2f carer support
Description: Centre-based carer support programme for dementia carers provided in a community care service centre, which provide group education on caring skills, mutual support groups, and group-based self-care training over 6 months.
Study NCT05783414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: f2f carer support
Description: Centre-based carer support programme for dementia carers provided in a community care service centre, which provide group education on caring skills, mutual support groups, and group-based self-care training over 6 months.
Study NCT05783414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vCST
Description: A home-based version of f2f CST delivered via an information and communication technology platform (Zoom plus a web-based CST platform). It consists of 14 sessions of group activities (group size: 3) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
Study NCT05783414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online carer support
Description: A home-based carer support service delivered via an information and communication technology platform (Zoom plus a web-based carer platform). It consists of 4 group sessions (group size: 6) and 3 individual sessions, and 3 optional self-learning sessions over 6 months, with an empowering care management approach to strengthen carer self-efficacy.
Study NCT05858892 — intervention group
Intervention type: OTHER
Intervention: usual care
Description: usual care(rehabilitation program)
Study NCT05107570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold exposure
Description: Cold air exposure (\~ 9°C, maximum 1 hour duration)
Study NCT06674525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 626
Description: Single subcutaneous injection
Study NCT06674525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection
Study NCT06704724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy (antimetabolite)
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Taxane-type Chemotherapy
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Monoclonal Antibody (EGFR Inhibitor)
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part of FOLFOX chemotherapy regimen~Folic Acid Analog
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: VEG-F inhibitor
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor (PD-1 inhibitor
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: immune checkpoint inhibitor (PD-1 inhibitor)
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Can be used in Platinum-based Chemotherapy regimen~Antimetabolite
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Can be used in Platinum-based chemotherapy regimen~Taxane
Study NCT06223646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR T-cells
Description: KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
Study NCT05041790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Alfoscerate
Description: Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
Study NCT05041790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)
Study NCT05308134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard fortification
Description: Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
Study NCT05308134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Target fortification
Description: Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
Study NCT05308134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BUN adjustable fortification
Description: BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
Study NCT05372991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-009
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Study NCT05372991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Study NCT05372991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Study NCT05587933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: cholecystectomy
Study NCT05587933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antispasmodic
Description: Antispasmodic
Study NCT06406959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominal plane block (TAP block)
Description: Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision
Study NCT05027204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
Study NCT05027204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, Q3W, i.v. 30 min
Study NCT06551597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extremely low frequency electromagnetic fields stimulation
Description: * In Group MT1, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - head, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* In Group MT2, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - pelvis, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* The control group participants will receive only neurological rehabilitation.
Study NCT06551597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extremely low frequency electromagnetic fields stimulation
Description: * In Group MT1, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - head, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* In Group MT2, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - pelvis, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* The control group participants will receive only neurological rehabilitation.
Study NCT05978089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxinshi tablet
Description: The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
Study NCT05978089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yangxinshi tablet simulants
Description: The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
Study NCT06347848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation Focused on Reducing Internalized Stigma
Description: Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break.
Study NCT04728802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proxalutamide
Description: Proxalutamide 300mg q.d
Study NCT04728802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study NCT05423132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
Study NCT05423132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological serum injection
Description: The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
Study NCT06704724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: SHP2 Inhibitor
Study NCT06725576 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation
Description: Thyroid ablation performed under ultrasound guidance to treat low-risk papillary thyroid carcinoma.
Study NCT06726278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400mcg Tab
Description: Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.
Study NCT06726278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
Study NCT04850170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: 1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow.
Study NCT04850170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speech therapy
Description: include the stretching of the neck, facial and oral movement training, and swallowing training
Study NCT04850170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: include the stretching of the neck, facial and oral movement training, and swallowing training
Study NCT05255939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal TRA group
Description: dTRA for PCI procedure to ACS patients.
Study NCT04434885 — intervention group
Intervention type: OTHER
Intervention: Clinical and imaging examination of symptoms and signs suggestive of axial involvement
Description: Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
Study NCT05233436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally
Study NCT06725134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy dog presence
Description: A trained therapy dog will be present during the child's dental appointment. The dog will be in the operatory as the child enters the room and will lie on the child during injection of local anesthesia.
Study NCT05255939 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional TRA group
Description: Conventional TRA for PCI procedure to ACS patients
Study NCT06725134 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care basic behavior guidance
Description: Basic behavior guidance as defined by the American Academy of Pediatric Dentistry includes strategies to help children cope through potentially stressful dental procedures. These strategies include tell-show-do, positive reinforcement, parental presence, and nitrous oxide/oxygen analgesia, among others.
Study NCT06568510 — intervention group
Intervention type: PROCEDURE
Intervention: Continuous peripheral nerve block
Description: A perineurial catheter is placed to a nerve structure through a Touchy needle
Study NCT05243160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication review
Description: The intervention consist of a medication review by a clinical pharmacologist.
Study NCT05523115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heights Smart Supplement
Description: The ingredient list of the product includes the following:~Algae oil Blueberry Extract Methylcobalamin (Vitamin B12) Cholecalciferol (Vitamin D3) Ascorbic acid (Vitamin C) Retinol acetate (Vitamin A) Calcium L-methylfolate (Folic Acid) D-biotin Pyridoxine hydrochloride (Vitamin B6) Calcium pantothenate (Vitamin B5) Nicotinamide (Vitamin B3) Riboflavin (Vitamin B2) Thiamine hydrochloride (Vitamin B1) D-Alpha tocopheryl acetate (Vitamin E) Chromium picolinate Potassium iodide Iron Citrate Sodium selenite Zinc citrate
Study NCT05138315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metamorphopsia quantification
Description: Alleye App and M.chart examinations will be performed pre- and postsurgically.
Study NCT04887753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronisation abilities
Description: The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
Study NCT04887753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronisation abilities
Description: The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.